🔗 Share this article

As the United States continues making sweeping adjustments to its immunization schedules, one figure has emerged somewhat surprisingly: Tracy Beth Høeg, a US-based sports medicine doctor and public health researcher who first made her name by expressing skepticism about coronavirus shots during the global health crisis and has concentrated on alleged deaths following Covid immunization in her short tenure at the Food and Drug Administration.

Planned Shifts to Pediatric Immunization Schedule

Agency leaders were set to unveil major changes to the pediatric immunization program recently, bringing the US with Denmark’s vaccine program, according to reports – a significant shift that would place the US out of step with a large portion of the world with little proof for benefit. The planned update has been pushed back until the next year.

Rather than Vinay Prasad, Høeg is scheduled to address the audience at the event. She was just designated interim head of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth appointee to run the division this calendar year.

A New Direction at the FDA

The acting appointment might represent a strengthened alliance between the drug and vaccine divisions as Høeg and Prasad strengthen their influence at the regulatory agency – and it suggests a greater focus upon rolling back previously authorized vaccines at the FDA.

Dr. Høeg has repeatedly called for halting specific childhood vaccine recommendations in the US in order to be more similar to the Danish model, a society with comprehensive healthcare and a population roughly the population of the state of Wisconsin.

So far public appearances, she has persisted in emphasizing on immunizations – traditionally the responsibility of Prasad, chief of the FDA’s Center for Biologics Evaluation and Research (CBER) – instead of medication approval.

Questions Over Qualifications

Dr. Høeg has little discernible experience in medication creation, regulation or management, which has been customary for former directors of the Center for Biologics Evaluation and Research. She has worked at the FDA as a key advisor to the agency head and CBER since March.

“It seems she lacks to have any of the qualifications” for running the drug-regulation department, remarked Jonathan Howard. “She has not conducted a clinical trial. She has no expertise in managing a sizeable institution. She has no expertise in pharmaceutical oversight.”

Previous commissioners of the center would “understand regulatory frameworks and the research of drug development”, noted Janet Woodcock. “Frankly, she lacks the kind of background that previous people who ran the center have had.”

CDER has an vast range of responsibilities at the agency, she stated.

“Many people just pays attention on the new drug program, but the generic program clears a multitude of generic drugs. There’s a biologic copycat branch, over-the-counter program and other areas, and every single one have to be supervised,” Woodcock noted. “The area you overlook, that is the part that I always told people is going to come back to haunt you.”

Furthermore, a substantial leadership aspect to the job, which oversees over 5,000 employees. “It is a massive management job, if you perform it correctly,” the former official concluded.

Response and Controversial Programs

In response to questions about Dr. Høeg's qualifications and whether this assignment represents increased cooperation among agency officials on immunizations, a press secretary said that the “inquiries stem from incorrect premises”.

“Her experience matches the responsibilities of her role,” the spokesperson said, citing the period Dr. Høeg spent guiding the agency head on “pharmaceutical safety and oversight research, including computational safety modeling and shot safety tracking”.

As the temporary head, Høeg assumes responsibility for the commissioner’s new fast-track approval initiative, a disputed one-day therapy clearance system that allegedly troubled her predecessors. “How are these medications being picked for this expedited pathway? Who makes the calls?” Howard asked. “There is a lot of secrecy going on at the agency right now.”

Broadly speaking, he remarked, “the FDA appears to be shifting towards less stringent rules of pharmaceuticals, aside from shots.”

Established Past Work on Vaccines

Regarding vaccines, Høeg has a more established, if concerning, history, some experts observe. She published a study using unverified public submissions to assess the incidence of heart inflammation following COVID-19 vaccination. She consulted for the Florida top health official Joseph Ladapo, who was said to have modified findings to suggest Covid vaccines are more dangerous than they are.

Part of her “desired changes” for the current federal leadership included changing guidelines for recently developed shots and discontinuing “optional” immunizations, she stated following the vote on a online show. At the FDA, Dr. Høeg has according to sources proposed preventing adolescent males from receiving COVID-19 vaccinations.

“She is an complete dogmatist who begins with her preconceived notions and works backwards to retrofit the data in a extremely disingenuous, dishonest way,” Howard stated.

Taking Control and a “Campaign of Retribution”

Høeg joined fellow dissenters, {like|